From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2018 call → NOWe need answer YES or NO. Need analyze transcript. Question asks whether management describes recently crossed into approved/specified/listed/qualified/reimbursed etc. inside buyers' systems, so future business can arrive without discrete selling event, and conveys new enough that most volume ahead. We need look at transcript. Management discusses CMS National Coverage Determination on NGS testing, FDA approvals, partnerships with Loxo and BMS for companion diagnostics, 23andMe FDA authorization, Harvard Pilgrim study, etc. But need specific: company has recently crossed into being approved/specified/listed etc. inside buyers' purchasing/reimbursement systems. Management mentions CMS NCD on NGS testing, which is a reimbursement pathway. But is that for Illumina? It's for NGS-based panels generally, not specifically Illumina. They say "our customers are seeing mounting awareness and acceptance of NGS-based panels. These tests like those offered by Foundation and Guardant are leading to increase demand for sequencing consumables." That's not Illumina being placed into a pathway. They mention "recent coverage decisions which demonstrate how the regulatory and reimbursement environment is progressing." But not that Illumina itself is now in a pathway. They mention partnerships with Loxo and BMS to develop companion diagnostics. Those are collaborations, not yet approved. They say "We are partnering with Loxo Oncology to gain approval for our TruSight Tumor 170 test as a companion diagnostic" - that's pending, not yet approved. "With BMS, we are working on companion diagnostic version" - not yet. So no. They mention 23andMe FDA authorization for direct-to-consumer genetic test for cancer risk. That's 23andMe, not Illumina. It broadens opportunity for personal genome companies. Not Illumina's own access. They mention "CMS National Coverage Determination on NGS testing" - that's a reimbursement pathway for NGS-based tests, but not specifically Illumina's products. It might benefit customers, but not Illumina being placed into a system. Also, it's a recent coverage decision, but management doesn't say Illumina is now inside a pathway such that orders arrive without selling. They say "These tests like those offered by Foundation and Guardant are leading to increase demand for sequencing consumables." That's indirect. They mention "In the U.S.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.